Client News

MagForce AG: MagForce USA, Inc. has Received FDA’s Approval to Proceed with Stage 2B with the Final Protocol of the Pivotal U.S. Study for the Focal Ablation of Prostate Cancer with the NanoTherm Therapy System

InflaRx Reports Third Quarter 2021 Financial & Operating Results

HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences

Imcyse Appoints Gene Mack, MBA as Chief Financial Officer

XPhyto Announces Managing Director Appointment, Financing and 3a-diagnostics Development

MagForce AG Publishes Financial Results for H1/2021 and Operative Highlights

Temedica Appoints Dr Christina Wagner as Chief Financial Officer

Marinomed updates financial calendar and participates in upcoming industry and investor conferences

InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum

Adocia announces 2021 third quarter financial results and a financing of €7 million through the issuance of convertible bonds subscribed by European investors and ordinary shares subscribed by Gérard Soula, Adocia co-founder